Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) has declared a quarterly cash dividend of $0.21 per share on common stock, payable on October 29, 2021, to record holders as of September 30, 2021. Additionally, the company announced dividends for its Series A and Series B Mandatory Convertible Preferred Stock: $11.875 and $12.50 per share, respectively, both payable on October 15, 2021, to holders of record on September 30, 2021.
SCIEX has launched the BioPhase 8800 system, a groundbreaking capillary electrophoresis solution enabling simultaneous processing of eight samples. This innovation addresses the growing complexities in biopharmaceutical development, enhancing the speed and accuracy of analyses critical for next-gen drug development. Key features include high throughput, integrated detection modules, and user-friendly software, promising to shorten analysis time from one month to just one week. As part of Danaher (NYSE: DHR), SCIEX continues to lead in solutions that enhance bioprocessing efficiency.
SCIEX, a Danaher company, has launched Biologics Explorer software for the ZenoTOF 7600 system, enhancing protein characterization analysis for biopharmaceuticals. This software enables scientists to optimize processing steps, delivering actionable insights from complex protein spectra. The strategic partnership with Genedata promotes further capabilities, allowing workflows for intact analysis, PTM determination, peptide mapping, and more. This innovation aims to expedite the development of life-saving protein therapeutics, illustrating SCIEX's commitment to advancing biopharma technology.
Danaher Corporation (NYSE: DHR) has successfully completed its acquisition of Aldevron, which will now function as a standalone entity within Danaher's Life Sciences segment. The acquisition aligns with Danaher's commitment to solving complex challenges in various sectors, including health care. With a diverse team of approximately 69,000 associates, Danaher aims to leverage this acquisition to enhance its operational capabilities and market position.
Danaher Corporation (NYSE: DHR) will conduct a live video webcast of its Investor and Analyst Meeting on September 9, 2021, starting at 12:00 p.m. ET. The event features President and CEO Rainer M. Blair and will be accessible via Danaher's website under the 'Investors' section. Attendees can find a link to the webcast and accompanying slides, while a replay will be available post-presentation. Danaher specializes in science and technology innovation, focusing on health care, environmental, and applied markets.
Danaher Corporation (NYSE: DHR) announced significant leadership changes effective April 1, 2022. Georgeann F. Couchara will succeed Angela S. Lalor as Senior Vice President of Human Resources, while Christopher M. Bouda will take over as Chief Accounting Officer from Robert S. Lutz on January 1, 2022. Both transitions aim to enhance the company's strategic focus on talent and finance. Lalor and Lutz will support the transition in advisory roles until their retirements in 2023 and 2022, respectively. Danaher emphasizes its commitment to fostering a robust leadership pipeline.
Danaher Corporation (NYSE: DHR) announced the passing of former President & CEO George M. Sherman, who led the company from 1990 to 2001. During his tenure, Danaher's sales grew five-fold and market capitalization increased over 20 times, primarily through strategic acquisitions. Sherman transformed Danaher into a focused global corporation and established the Danaher Business System as its operating philosophy. Chairman Steven M. Rales expressed deep condolences and highlighted Sherman's lasting influence on the company.
Danaher Corporation (NYSE: DHR) announced a significant investment plan from its subsidiaries, Cytiva and Pall Corporation, totaling 1.5 billion USD over the next two years. This investment will enhance manufacturing capacity for key products used in biologic medicines across multiple geographies, including the US, UK, Austria, China, and other regions. Specific allocations include 600 million USD for chromatography resins, 400 million USD for cell culture media, and 300 million USD for single-use technologies. The initiative aims to address supply chain challenges and improve overall manufacturing agility.
Beckman Coulter has finalized agreements with Quidel Corporation to acquire rights for the BNP assay, previously sold as TRIAGE® BNP. Beckman Coulter will exclusively manufacture and market the Access BNP assay, transitioning distribution from Quidel globally. The agreements resolve ongoing litigation and disputes between the two companies. This addition expands Beckman Coulter's cardiovascular diagnostic offerings, crucial for managing cardiovascular diseases, which account for 31% of global deaths. The Access BNP assay aids in diagnosing heart failure, enhancing patient care.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q2 2021, achieving net earnings of $1.7 billion, a remarkable 84% increase year-over-year. Diluted earnings per share reached $2.28, with non-GAAP adjusted earnings at $2.46, up 71%. Revenues surged to $7.2 billion, reflecting a 36.5% year-over-year growth. Operating cash flow rose by 46.5% to $2.1 billion, and free cash flow increased by 41% to $1.8 billion. For Q3 2021, Danaher forecasts mid- to high-teens percent non-GAAP core revenue growth and a full-year estimate of approximately 20% growth.